What To Expect When IBD 50's No. 2, Hims & Hers, Reports Amid The Semaglutide Battle

byiShook Opinion
Feb 24, 2025 - 15:10

Share

Compounding pharmacy and IBD 50 newcomer Hims & Hers Health is expected late Monday to report bullish earnings and sales growth. The post What To Expect When IBD 50's No. 2, Hims & Hers, Reports Amid The Semaglutide Battle appeared first on Investor's Business Daily.

Compounding pharmacy and IBD 50 newcomer Hims & Hers Health is expected late Monday to report bullish earnings and sales growth.

The post What To Expect When IBD 50's No. 2, Hims & Hers, Reports Amid The Semaglutide Battle appeared first on Investor's Business Daily.